Celcuity Inc (CELC)

$83.45 -2.04 (-2.39%)
Market Cap 4.08B
Revenue (ttm) 0.00
Net Income (ttm) -177.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 863,300
Avg Vol 1,202,044
Day's Range N/A - N/A
Shares Out 48.93M
Stochastic %K 1%
Beta 0.19
Analysts Strong Sell
Price Target $161.09

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology
Sector: Healthcare
Phone: (763) 392-0123
Address:
2800 Campus Drive, Suite 140, Minneapolis, United States
OMillionaires
OMillionaires Sep. 12 at 6:08 PM
Of course now I am trying to see if there is any significance to $CRBP 's Friday press release for Monday data and conference call... A few: Celcuity ($CELC )Friday notice: July 25, 2025 Monday results: July 28, 2025 IDEAYA ($IDYA)Friday notice: April 10, 2026 Monday results: April 13, 2026
3 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Sep. 12 at 10:13 AM
$CELC CELC already has something AstraZeneca doesn’t get from today’s result: positive Phase 3 evidence for gedatolisib in another HR+/HER2- setting. In PIK3CA-mutant VIKTORIA-1, Celcuity reported roughly a 50% reduction in risk of progression/death, with median PFS of 11.1 months for the triplet versus 5.6 months for alpelisib + fulvestrant. And Revtorpyk is already FDA-approved in the PIK3CA wild-type population, with the mutant sNDA submitted August 26.
0 · Reply
Lussu1986
Lussu1986 Sep. 11 at 10:24 PM
$CELC AZN SERENA-4 Failure announced after close net positive for CELC
1 · Reply
justiceforb_85
justiceforb_85 Sep. 11 at 9:04 PM
$CELC revtorpyk will be a blockbuster.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Sep. 10 at 8:06 PM
$CELC swinging this hard margin . See you at $98
0 · Reply
sfido7
sfido7 Sep. 10 at 6:39 PM
$CELC ....lower lows, acts like someone big wants out
0 · Reply
Dragonland
Dragonland Sep. 10 at 2:07 PM
$CELC 5 days down now. Is this ever getting off the canvas? Every time it gets to 95 it gets smacked down.
2 · Reply
Quantumup
Quantumup Sep. 9 at 12:56 PM
TD Cowen🏁 $FTH at a Buy and said -- Multi-node PAM inhibition is validated and can result in improved outcomes in breast cancer and likely beyond. $CELC $RLAY NVS RHHBY AZn TD Cowen added—PIKTOR's oral administration and differentiated PK should achieve strong adoption through a favorable, practical balance of efficacy through exposure, tolerability, and convenience. Phll endometrial data by YE should validate its profile and support a $2B+ opportunity across indications.
1 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Sep. 9 at 12:30 PM
$CELC Great call! Motivated
0 · Reply
Merlintrader
Merlintrader Sep. 6 at 7:49 PM
Celcuity ($CELC) Stock Hub: sNDA Filed for the PIK3CA-Mutant Cohort, First REVTORPYK Shipments Guided for Late Quarter and Two September Fireside Chats Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/celc-celcuity-inc/
0 · Reply
Latest News on CELC
Celcuity Transcript: Citigroup’s Biopharma Back to School Summit 2026

Sep 9, 2026, 8:00 AM EDT - 4 days ago

Celcuity Transcript: Citigroup’s Biopharma Back to School Summit 2026

Celcuity Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 8, 2026, 10:15 AM EDT - 5 days ago

Celcuity Transcript: Wells Fargo 21st Annual Healthcare Conference

Celcuity To Participate in Upcoming Investor Conferences

Sep 1, 2026, 8:30 AM EDT - 12 days ago

Celcuity To Participate in Upcoming Investor Conferences

Celcuity submits Revtorpyk sNDA to the FDA

2026-08-26T12:40:23.000Z - 18 days ago

Celcuity submits Revtorpyk sNDA to the FDA

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

Aug 26, 2026, 8:30 AM EDT - 18 days ago

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

Celcuity price target raised to $175 from $165 at Guggenheim

2026-08-17T11:06:45.000Z - 27 days ago

Celcuity price target raised to $175 from $165 at Guggenheim

Celcuity reports Q2 EPS ($1.07), consensus ($1.16)

2026-08-16T14:11:38.000Z - 4 weeks ago

Celcuity reports Q2 EPS ($1.07), consensus ($1.16)

Celcuity price target lowered to $150 from $175 at Stifel

2026-08-16T13:44:29.000Z - 4 weeks ago

Celcuity price target lowered to $150 from $175 at Stifel

Celcuity price target lowered to $140 from $157 at Needham

2026-08-16T13:14:00.000Z - 4 weeks ago

Celcuity price target lowered to $140 from $157 at Needham

Celcuity Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 4 weeks ago

Celcuity Earnings Call Transcript: Q2 2026

Celcuity Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 4 weeks ago

Celcuity Earnings release: Q2 2026

Celcuity Quarterly report: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 4 weeks ago

Celcuity Quarterly report: Q2 2026

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 13, 2026, 4:06 PM EDT - 4 weeks ago

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

Aug 6, 2026, 8:34 AM EDT - 5 weeks ago

Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law

Aug 2, 2026, 5:27 PM EDT - 5 weeks ago

CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law

Celcuity announces NCCN recommendation for Revtorpyk combination

2026-07-30T13:40:33.000Z - 6 weeks ago

Celcuity announces NCCN recommendation for Revtorpyk combination

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Jul 30, 2026, 8:30 AM EDT - 6 weeks ago

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Short Report: Bears book profits in Celcuity

2026-07-26T14:50:08.000Z - 7 weeks ago

Short Report: Bears book profits in Celcuity

ARRY BOBS PVLA STAA

Celcuity falls -19.7%

2026-07-15T16:06:36.000Z - 2 months ago

Celcuity falls -19.7%

Celcuity falls -12.6%

2026-07-15T14:00:12.000Z - 2 months ago

Celcuity falls -12.6%

Celcuity price target raised to $178 from $171 at Craig-Hallum

2026-07-15T13:25:58.000Z - 2 months ago

Celcuity price target raised to $178 from $171 at Craig-Hallum

Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

Jul 15, 2026, 8:43 AM EDT - 2 months ago

Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

Celcuity price target raised to $155 from $145 at H.C. Wainwright

2026-07-15T10:00:15.000Z - 2 months ago

Celcuity price target raised to $155 from $145 at H.C. Wainwright

Celcuity price target raised to $177 from $160 at Citizens

2026-07-15T09:51:28.000Z - 2 months ago

Celcuity price target raised to $177 from $160 at Citizens

Celcuity Transcript: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 2 months ago

Celcuity Transcript: FDA announcement

Celcuity Press release: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 2 months ago

Celcuity Press release: FDA announcement

Celcuity Slides: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 2 months ago

Celcuity Slides: FDA announcement

Celcuity announces FDA approval of Revtorpyk

2026-07-14T20:55:11.000Z - 2 months ago

Celcuity announces FDA approval of Revtorpyk

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

Jul 14, 2026, 4:53 PM EDT - 2 months ago

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

Celcuity Slides: Corporate presentation

Jul 14, 2026, 4:00 PM EDT - 2 months ago

Celcuity Slides: Corporate presentation

US FDA approves Celcuity's breast cancer drug

Jul 14, 2026, 3:29 PM EDT - 2 months ago

US FDA approves Celcuity's breast cancer drug

FDA approves Celcuity’s gedatolisib combo for certain breast cancers

2026-07-14T19:15:10.000Z - 2 months ago

FDA approves Celcuity’s gedatolisib combo for certain breast cancers

Celcuity Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 8:00 AM EDT - 3 months ago

Celcuity Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Celcuity Slides: FY 2026

Jun 10, 2026, 8:00 AM EDT - 3 months ago

Celcuity Slides: FY 2026

Celcuity Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 1:25 PM EDT - 3 months ago

Celcuity Transcript: Jefferies Global Healthcare Conference 2026

Celcuity prices $500M convertible senior note offering

2026-06-04T11:42:59.000Z - 3 months ago

Celcuity prices $500M convertible senior note offering

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Jun 3, 2026, 10:13 PM EDT - 3 months ago

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Celcuity price target lowered to $171 from $189 at Craig-Hallum

2026-06-03T15:14:03.000Z - 3 months ago

Celcuity price target lowered to $171 from $189 at Craig-Hallum

Celcuity price target lowered to $166 from $183 at Wells Fargo

2026-06-03T11:46:12.000Z - 3 months ago

Celcuity price target lowered to $166 from $183 at Wells Fargo

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

Jun 3, 2026, 7:19 AM EDT - 3 months ago

Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032

Celcuity price target lowered to $145 from $185 at H.C. Wainwright

2026-06-03T10:21:27.000Z - 3 months ago

Celcuity price target lowered to $145 from $185 at H.C. Wainwright

Celcuity plunges after experimental breast cancer treatment data disappoints

Jun 2, 2026, 1:20 PM EDT - 3 months ago

Celcuity plunges after experimental breast cancer treatment data disappoints

Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer

Jun 2, 2026, 8:25 AM EDT - 3 months ago

Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer

Celcuity Transcript: Study result

Jun 2, 2026, 8:00 AM EDT - 3 months ago

Celcuity Transcript: Study result

Celcuity Press release: Study result

Jun 2, 2026, 8:00 AM EDT - 3 months ago

Celcuity Press release: Study result

Celcuity Slides: Study result

Jun 2, 2026, 8:00 AM EDT - 3 months ago

Celcuity Slides: Study result

Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

Jun 1, 2026, 8:30 AM EDT - 3 months ago

Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026

Celcuity Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 4 months ago

Celcuity Earnings Call Transcript: Q1 2026

Celcuity Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 4 months ago

Celcuity Earnings release: Q1 2026

Celcuity Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 4 months ago

Celcuity Quarterly report: Q1 2026

Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:01 PM EDT - 4 months ago

Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

May 14, 2026, 7:30 AM EDT - 4 months ago

Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

May 7, 2026, 8:00 AM EDT - 4 months ago

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

May 1, 2026, 5:03 PM EDT - 4 months ago

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Celcuity Proxy statement: Proxy filing

Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Celcuity Proxy statement: Proxy filing

Celcuity Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Celcuity Earnings Call Transcript: Q4 2025

Celcuity Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Celcuity Annual report: Q4 2025

Celcuity Earnings release: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Celcuity Earnings release: Q4 2025

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 25, 2026, 4:01 PM EDT - 5 months ago

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

Mar 18, 2026, 8:00 AM EDT - 5 months ago

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

Celcuity Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:20 PM EDT - 6 months ago

Celcuity Transcript: Leerink Global Healthcare Conference 2026

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Mar 9, 2026, 5:42 PM EDT - 6 months ago

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Celcuity Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 6 months ago

Celcuity Transcript: TD Cowen 46th Annual Health Care Conference

Celcuity Appoints Charles Romp to its Board of Directors

Feb 12, 2026, 4:05 PM EST - 7 months ago

Celcuity Appoints Charles Romp to its Board of Directors

Celcuity Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 9:30 AM EST - 7 months ago

Celcuity Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:05 AM EST - 7 months ago

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE COGT FBYD FRGE INBX KOD LITE

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Jan 20, 2026, 7:30 AM EST - 7 months ago

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Dec 11, 2025, 2:35 PM EST - 9 months ago

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Celcuity Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 7:30 AM EST - 9 months ago

Celcuity Transcript: Evercore ISI 8th Annual HealthCONx Conference

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Nov 26, 2025, 4:05 PM EST - 9 months ago

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

Nov 26, 2025, 7:05 AM EST - 9 months ago

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Nov 17, 2025, 4:05 PM EST - 9 months ago

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Celcuity Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Celcuity Earnings Call Transcript: Q3 2025

Celcuity Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Celcuity Quarterly report: Q3 2025

Celcuity Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Celcuity Earnings release: Q3 2025

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 10 months ago

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:00 AM EST - 10 months ago

Celcuity Transcript: Stifel 2025 Healthcare Conference

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Nov 5, 2025, 7:05 AM EST - 10 months ago

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:05 AM EST - 10 months ago

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

Oct 20, 2025, 9:42 AM EDT - 10 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CRMD RANI RAPT

Celcuity Transcript: Study Result

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Celcuity Transcript: Study Result

Celcuity Press release: Study Result

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Celcuity Press release: Study Result

Celcuity Slides: Study Result

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Celcuity Slides: Study Result

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Oct 18, 2025, 4:30 AM EDT - 11 months ago

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Oct 18, 2025, 4:30 AM EDT - 11 months ago

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Oct 18, 2025, 4:30 AM EDT - 11 months ago

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Celcuity Slides: Corporate Presentation

Oct 16, 2025, 7:00 AM EDT - 11 months ago

Celcuity Slides: Corporate Presentation

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Sep 22, 2025, 9:15 AM EDT - 11 months ago

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Sep 9, 2025, 4:01 PM EDT - 1 year ago

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Aug 27, 2025, 4:05 PM EDT - 1 year ago

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Celcuity Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings Call Transcript: Q2 2025

Celcuity Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings release: Q2 2025

Celcuity Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Quarterly report: Q2 2025

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 1 year ago

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Aug 7, 2025, 7:05 AM EDT - 1 year ago

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

OMillionaires
OMillionaires Sep. 12 at 6:08 PM
Of course now I am trying to see if there is any significance to $CRBP 's Friday press release for Monday data and conference call... A few: Celcuity ($CELC )Friday notice: July 25, 2025 Monday results: July 28, 2025 IDEAYA ($IDYA)Friday notice: April 10, 2026 Monday results: April 13, 2026
3 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Sep. 12 at 10:13 AM
$CELC CELC already has something AstraZeneca doesn’t get from today’s result: positive Phase 3 evidence for gedatolisib in another HR+/HER2- setting. In PIK3CA-mutant VIKTORIA-1, Celcuity reported roughly a 50% reduction in risk of progression/death, with median PFS of 11.1 months for the triplet versus 5.6 months for alpelisib + fulvestrant. And Revtorpyk is already FDA-approved in the PIK3CA wild-type population, with the mutant sNDA submitted August 26.
0 · Reply
Lussu1986
Lussu1986 Sep. 11 at 10:24 PM
$CELC AZN SERENA-4 Failure announced after close net positive for CELC
1 · Reply
justiceforb_85
justiceforb_85 Sep. 11 at 9:04 PM
$CELC revtorpyk will be a blockbuster.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Sep. 10 at 8:06 PM
$CELC swinging this hard margin . See you at $98
0 · Reply
sfido7
sfido7 Sep. 10 at 6:39 PM
$CELC ....lower lows, acts like someone big wants out
0 · Reply
Dragonland
Dragonland Sep. 10 at 2:07 PM
$CELC 5 days down now. Is this ever getting off the canvas? Every time it gets to 95 it gets smacked down.
2 · Reply
Quantumup
Quantumup Sep. 9 at 12:56 PM
TD Cowen🏁 $FTH at a Buy and said -- Multi-node PAM inhibition is validated and can result in improved outcomes in breast cancer and likely beyond. $CELC $RLAY NVS RHHBY AZn TD Cowen added—PIKTOR's oral administration and differentiated PK should achieve strong adoption through a favorable, practical balance of efficacy through exposure, tolerability, and convenience. Phll endometrial data by YE should validate its profile and support a $2B+ opportunity across indications.
1 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Sep. 9 at 12:30 PM
$CELC Great call! Motivated
0 · Reply
Merlintrader
Merlintrader Sep. 6 at 7:49 PM
Celcuity ($CELC) Stock Hub: sNDA Filed for the PIK3CA-Mutant Cohort, First REVTORPYK Shipments Guided for Late Quarter and Two September Fireside Chats Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/celc-celcuity-inc/
0 · Reply
TheTarkioTrader
TheTarkioTrader Sep. 3 at 8:53 PM
$CELC About the short positions • CELC - Increased crowded short since Jun (Figure 3), indicate bearish views of gedatolisib's OS benefits in HR+/HER2-/РIK3CA WT breast cancer and competitive differentiation vs. other PIK-pathway inhibitors. More recently, investors are increasingly concerned about gedatolisib (Revtorpyk)'s slower-than-expected launch timeline. The company delayed drug shipment to late-3Q as the they await FDA sign-off for a secondary manufacturing facility. Chill Banker @ChillBanking Follow
1 · Reply
vu_jade
vu_jade Sep. 3 at 7:03 PM
$CELC enter
0 · Reply
TheTarkioTrader
TheTarkioTrader Sep. 3 at 5:15 PM
$CELC how can this be red? Would you believe it unbelievable especially with the market high and everything has got going for it crazy
1 · Reply
TheTarkioTrader
TheTarkioTrader Sep. 3 at 11:08 AM
$CELC big premarket a little after 6 AM central standard time over 5000 shares usually there’s a few hundred
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Sep. 2 at 9:45 PM
$CELC
0 · Reply
PB09
PB09 Sep. 2 at 8:08 PM
$CELC touch that $110 so I can get out. Have seen enough fuckery here
0 · Reply
Stocks2Retire
Stocks2Retire Sep. 2 at 6:44 PM
$CELC multiple attempts at breaking out of 85-95 range.. we will finally get there!
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Sep. 2 at 6:39 PM
$CELC
0 · Reply
TheTarkioTrader
TheTarkioTrader Sep. 2 at 1:42 PM
$CELC
0 · Reply
TheTarkioTrader
TheTarkioTrader Sep. 1 at 8:00 PM
$CELC crazy last hour about 400,000 shares rated maybe more big price went to the upside something’s going down with his bad boy
0 · Reply
TheTarkioTrader
TheTarkioTrader Sep. 1 at 12:55 PM
$CELC Coming after CELC? 😂 I wouldn’t be so sure. KZIA certainly has an interesting story, but you’re comparing a drug with a lot of future potential to CELC, where Revtorpyk already has FDA approval and NCCN Category 1 recognition. That’s a pretty big difference between “this could become a multibillion-dollar drug” and having the regulatory and clinical validation already in hand. And don’t overlook CELC’s biomarker-driven approach. The ability to identify the patients most likely to respond is a huge part of the story here. If Revtorpyk continues to demonstrate what we think it can, the commercial opportunity could be enormous. So by all means, enjoy KZIA. But if you’re “coming after” CELC, you better bring your lunch. 😎 I’ll take CELC’s head start over a prediction of where KZIA might be several years from now.
2 · Reply
TW_Research
TW_Research Sep. 1 at 12:09 PM
$KZIA Lots of news out today along with a conference call going on now. The news here is beyond exciting when you consider this is clearly the best in class PI3K/MTOR inhibitor and has just now opened up new indications. This will soon enough be a multi-billion dollar drug and the current market cap (fully diluted) is under $300M. REalize that when I say fully diluted, that would mean they have $140M of cash if the warrants are exercised. Fully funded and off to the races. Thanks for sharing this drug with us $RHHBY . Coming after you $CELC .
2 · Reply